Adtalem's Q1 Revenue Jumps 10.7%, Net Income Up 33.9%

TL;DR

**Adtalem is crushing it with double-digit revenue and profit growth, buy the dip!**

AI Summary

Adtalem Global Education Inc. (ATGE) reported a strong financial performance for the three months ended September 30, 2025, the first quarter of fiscal year 2026. Revenue increased by 10.7% to $462.288 million, up from $417.400 million in the prior-year period. Net income saw a significant rise of 33.9%, reaching $61.832 million compared to $46.165 million in the same quarter last year. Diluted earnings per share also improved substantially, climbing to $1.67 from $1.18. The company's cash and cash equivalents increased to $264.691 million from $199.601 million at June 30, 2025, reflecting robust cash flow from operating activities of $130.549 million. Key business changes include increased tuition and fees across all segments, with Chamberlain University revenue growing to $179.201 million and Walden University revenue to $189.960 million. Risks include ongoing litigation costs from discontinued operations, which incurred $0.8 million in income from discontinued operations, and the impact of new accounting standards like ASU 2026-06 on internal-use software. The strategic outlook appears positive, driven by strong enrollment and effective management of operating costs, despite a slight increase in cost of educational services to $200.767 million.

Why It Matters

This strong Q1 performance signals robust demand for Adtalem's healthcare education programs, particularly at Chamberlain and Walden Universities, which is crucial for investors seeking growth in the education sector. The significant increase in net income and cash flow provides financial flexibility for future investments or shareholder returns, potentially boosting investor confidence. For employees, stable growth often translates to job security and potential expansion opportunities. Customers, primarily students, benefit from a financially healthy institution that can invest in educational quality and resources. In a competitive landscape, Adtalem's ability to grow revenue and profitability while managing costs positions it favorably against other education providers, reinforcing its market leadership in healthcare education.

Risk Assessment

Risk Level: medium — The company faces medium risk due to ongoing litigation costs from discontinued operations, which resulted in $0.8 million in income from discontinued operations for the quarter, indicating continued legal expenses. Additionally, while revenue is up, accounts and financing receivables increased by $62.690 million, suggesting potential future collectability challenges, despite a provision for bad debts of $14.883 million. The company also has significant long-term debt of $553.152 million, which could pose a risk in a rising interest rate environment.

Analyst Insight

Investors should consider Adtalem's strong Q1 results as a positive indicator of its operational efficiency and market position in healthcare education. Given the significant revenue and net income growth, and robust cash flow, investors might consider increasing their position or initiating a new one, especially if the stock is trading at a reasonable valuation. Monitor future filings for trends in student enrollment and any material changes in litigation expenses or debt management strategies.

Financial Highlights

debt To Equity

0.97

revenue

$462.288M

operating Margin

18.5%

total Assets

$2,867.463M

total Debt

$553.152M

net Income

$61.832M

eps

$1.67

gross Margin

56.6%

cash Position

$264.691M

revenue Growth

+10.7%

Revenue Breakdown

Key Numbers

• $462.288M — Revenue (Increased by 10.7% from $417.400M year-over-year.)
• $61.832M — Net Income (Increased by 33.9% from $46.165M year-over-year.)
• $1.67 — Diluted EPS (Increased from $1.18 year-over-year.)
• $264.691M — Cash and cash equivalents (Increased from $199.601M at June 30, 2025.)
• $130.549M — Net cash provided by operating activities (Increased from $89.316M year-over-year.)
• $179.201M — Chamberlain University Revenue (Segment revenue for the quarter.)
• $189.960M — Walden University Revenue (Segment revenue for the quarter.)
• $93.127M — Medical and Veterinary Schools Revenue (Segment revenue for the quarter.)
• $553.152M — Long-term debt (Total long-term debt as of September 30, 2025.)
• $14.883M — Provision for bad debts (Expense for the quarter, up from $13.720M.)

Key Players & Entities

• Adtalem Global Education Inc. (company) — registrant
• Chamberlain University (company) — reportable segment
• Walden University (company) — reportable segment
• American University of the Caribbean School of Medicine (company) — medical and veterinary school
• Ross University School of Medicine (company) — medical and veterinary school
• Ross University School of Veterinary Medicine (company) — medical and veterinary school
• Cogswell Education, LLC (company) — purchaser of DeVry University
• Financial Accounting Standards Board (regulator) — issuer of accounting standards
• Securities and Exchange Commission (regulator) — regulator of financial reporting
• DeVry University (company) — discontinued operation

FAQ

Risk Factors

• Ongoing Litigation Costs [medium — legal]: The company incurs costs related to ongoing litigation from discontinued operations. For the three months ended September 30, 2025, there was $0.8 million in income from discontinued operations, indicating that while there are costs, they are currently outweighed by income from these operations.
• New Accounting Standards [low — regulatory]: Adtalem is subject to the impact of new accounting standards, such as ASU 2026-06 concerning internal-use software. The company must ensure compliance and adapt its financial reporting processes accordingly.

Industry Context

Adtalem operates in the post-secondary healthcare education sector, a field characterized by increasing demand for skilled professionals and evolving regulatory landscapes. The competitive environment includes both traditional universities and specialized for-profit education providers. Key trends involve the integration of technology in education delivery and a focus on graduate outcomes and employability.

Regulatory Implications

Adtalem faces regulatory oversight from various bodies, including accrediting agencies and government regulators. Compliance with evolving educational standards and financial aid regulations is crucial. The company must also navigate the impact of new accounting pronouncements, such as ASU 2026-06, on its financial reporting.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-09-30: End of First Quarter Fiscal Year 2026 — Reported strong revenue and net income growth, increased cash position, and positive operating cash flow.
• 2025-06-30: End of Fiscal Year 2025 — Previous period balance sheet data for comparison, showing $199.601M in cash and cash equivalents.

Glossary

ASU 2026-06

An Accounting Standards Update issued by the Financial Accounting Standards Board (FASB) that provides guidance on accounting for costs related to internal-use software. (This new standard may impact Adtalem's financial reporting, particularly concerning the capitalization and amortization of software development costs.)

Discontinued Operations

A component of a business that has been sold, disposed of, or is classified as held for sale, and whose operations and cash flows can be clearly distinguished from the rest of the company. (Adtalem continues to incur costs related to past discontinued operations, which are reported separately on the income statement.)

Treasury Stock

Stock that a company has repurchased from the open market but has not yet retired. It is shown as a contra-equity account. (Adtalem holds a significant amount of treasury stock, valued at $2,053.424M as of September 30, 2025, which reduces total shareholders' equity.)

Year-Over-Year Comparison

Compared to the prior-year period, Adtalem demonstrated robust financial performance in the first quarter of fiscal year 2026. Revenue surged by 10.7% to $462.288 million, and net income saw a substantial increase of 33.9% to $61.832 million, with diluted EPS rising to $1.67. The company also significantly improved its cash position, with cash and cash equivalents growing to $264.691 million, supported by strong operating cash flow. New risks identified include the impact of new accounting standards, while ongoing litigation from discontinued operations remains a factor.

Key Financial Figures

• $0.01 — ange on which registered Common stock, $0.01 par value per share ATGE New York S

Filing Documents

• atge-20250930x10q.htm (10-Q) — 2350KB
• atge-20250930xex31d1.htm (EX-31.1) — 10KB
• atge-20250930xex31d2.htm (EX-31.2) — 10KB
• atge-20250930xex32d1.htm (EX-32.1) — 8KB
• 0001104659-25-104397.txt ( ) — 10646KB
• atge-20250930.xsd (EX-101.SCH) — 60KB
• atge-20250930_cal.xml (EX-101.CAL) — 77KB
• atge-20250930_def.xml (EX-101.DEF) — 247KB
• atge-20250930_lab.xml (EX-101.LAB) — 597KB
• atge-20250930_pre.xml (EX-101.PRE) — 443KB
• atge-20250930x10q_htm.xml (XML) — 2109KB

Financial Information

Part I. Financial Information Item 1.

Financial Statements

Financial Statements 1 Consolidated Balance Sheets 1 Consolidated Statements of Income 2 Consolidated Statements of Cash Flows 3 Consolidated Statements of Shareholders' Equity 4

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 40

Other Information

Part II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 41 Item 5. Other Information 41 Item 6. Exhibits 42 Signature 43 Table of Contents

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements Adtalem Global Education Inc. Consolidated Balance Sheets (unaudited) (in thousands, except par value) September 30, June 30, 2025 2025 Assets: Current assets: Cash and cash equivalents $ 264,691 $ 199,601 Restricted cash 1,494 1,563 Accounts and financing receivables, net 194,837 146,189 Prepaid expenses and other current assets 106,195 68,837 Total current assets 567,217 416,190 Noncurrent assets: Property and equipment, net 257,357 256,131 Operating lease assets 189,762 191,194 Deferred income taxes — 32,956 Intangible assets, net 762,669 765,474 Goodwill 961,262 961,262 Other assets, net 129,196 129,145 Total noncurrent assets 2,300,246 2,336,162 Total assets $ 2,867,463 $ 2,752,352 Liabilities and shareholders' equity: Current liabilities: Accounts payable $ 104,576 $ 105,017 Accrued payroll and benefits 51,969 76,374 Accrued liabilities 62,812 77,286 Deferred revenue 322,867 214,091 Current operating lease liabilities 34,392 35,159 Total current liabilities 576,616 507,927 Noncurrent liabilities: Long-term debt 553,152 552,669 Long-term operating lease liabilities 188,406 186,172 Deferred income taxes 53,313 31,856 Other liabilities 38,352 40,103 Total noncurrent liabilities 833,223 810,800 Total liabilities 1,409,839 1,318,727 Commitments and contingencies Shareholders' equity: Common stock, $ 0.01 par value per share, 200,000 shares authorized; 36,324 and 35,952 shares outstanding as of September 30, 2025 and June 30, 2025, respectively 847 839 Additional paid-in capital 673,022 664,300 Retained earnings 2,839,406 2,777,574 Accumulated other comprehensive loss ( 2,227 ) ( 2,227 ) Treasury stock, at cost, 48,333 and 47,990 shares as of September 30, 2025 and June 30, 2025, respectively ( 2,053,424 ) ( 2,006,861 ) Total shareholders' equity 1,457,624 1,

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (unaudited) Table of Contents Note Page 1 Nature of Operations 6 2 Summary of Significant Accounting Policies 6 3 Discontinued Operations 7 4 Revenue 7 5 Restructuring Expense 9 6 Other Income, Net 9 7 Income Taxes 9 8 Earnings per Share 10 9 Accounts and Financing Receivables 10 10 Property and Equipment, Net 13 11 Leases 13 12 Goodwill and Intangible Assets 14 13 Debt 16 14 Share Repurchases 19 15 Stock-Based Compensation 19 16 Fair Value Measurements 21 17 Commitments and Contingencies 22 18 Segment Information 23 5 Table of Contents 1. Nature of Operations In this Quarterly Report on Form 10-Q, Adtalem Global Education Inc., together with its subsidiaries, is collectively referred to as "Adtalem," "we," "our," "us," or similar references. Adtalem reports on a fiscal year period ending on June 30. Therefore, this Quarterly Report for the quarterly period ended September 30, 2025 is for our first quarter of fiscal year 2026. Adtalem is the leading healthcare educator in the U.S. Our schools consist of Chamberlain University ("Chamberlain"), Walden University ("Walden"), American University of the Caribbean School of Medicine ("AUC"), Ross University School of Medicine ("RUSM"), and Ross University School of Veterinary Medicine ("RUSVM"). AUC, RUSM, and RUSVM are collectively referred to as the "medical and veterinary schools." "Home Office" includes activities not allocated to a reportable segment. See Note 18 "Segment Information" for information on our reportable segments. 2. Summary of Significant Accounting Policies Basis of Presentation Our significant accounting policies are described in Note 2 "Summary of Significant Accounting Policies" of our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the "2025 Form 10-K"). We have prepared the accompanying unaudited consolidated financial statements in accordance w